Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Alfred Chu

Cardiovascular Disease Amarillo, TX Medical Doctor

NPI 1922181916 CMS profile 360152

1901 Port Ln, Amarillo, TX 79106

Open in the dashboard

General payments

$5,538

74 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,260,501 paid to institutions, not to them · program years 2019–2023

Through program year 2023, Alfred Chu of Amarillo, TX is reported in the CMS Open Payments database as having received $5,538 across 74 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,260,501 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 71st percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $20 1
2022 General $306 6
2021 General $1,705 26
2020 General $607 17
2019 General $2,899 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alfred Chu
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Alfred Chu were reported at $0. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Alfred Chu Cardiovascular Disease median Middle half National median
2019 $2,899 $450 $127–$1,392 $163
2020 $607 $242 $77–$751 $114
2021 $1,705 $335 $101–$1,037 $132
2022 $306 $395 $121–$1,211 $149
2023 $20 $443 $136–$1,283 $160
2024 $0 $450 $136–$1,323 $164
2025 $0 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Abiomed $2,658 15 payments
  2. Abbott Laboratories $1,365 46 payments
  3. Cordis US Corp. $1,017 2 payments
  4. Amarin Pharma Inc. $202 2 payments
  5. Medtronic Vascular, Inc. $103 1 payment
  6. Boston Scientific Corporation $82 1 payment
  7. E.R. Squibb & Sons, L.L.C. $20 1 payment
  8. Cardinal Health 200, LLC $20 1 payment
  9. Amgen Inc. $19 1 payment
  10. Medtronic, Inc. $16 1 payment
  11. Other $37 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $3,351 70 payments
  2. Travel and Lodging $1,187 3 payments
  3. Consulting Fee $1,000 1 payment
Products named General payments · program years 2019–2023
  1. Impella $2,658 15 payments
  2. Perclose ProGlide suture mediated closure system $269 7 payments
  3. Xience Sierra Coronary Stent System $259 6 payments
  4. Vascepa $202 2 payments
  5. Supera peripheral stent system $186 8 payments
  6. Xience Sierra Coronary Stent Vascular $111 3 payments
  7. Reveal LINQ $103 1 payment
  8. Xience Sierra Coronary Stent Cardiac Arrhythmias and Heart Failure $97 3 payments
  9. JETi Peripheral Catheter $87 1 payment
  10. PERCLOSE PROGLIDE $86 1 payment
  11. Other $471 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

74 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record